Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%

Artiva Biotherapeutics has announced a strategic update that involves the immediate discontinuation of its autoimmune cell therapy development. According to reports from Reuters, STAT, and BioPharma Dive, the company is exiting this specific area of research following the deaths of two patients. As a direct consequence of these clinical failures and the decision to cease operations in this sector, the company is implementing a massive workforce reduction. Fierce Biotech reports that the layoffs will affect 94% of the company's staff, marking a near-total collapse of its operational capacity. Coverage from multiple outlets, including Yahoo Finance and BioPharma Dive, emphasizes the specific product being abandoned: the AlloNK® platform. The reporting highlights that the decision was not based solely on the tragic loss of patient life, but also on issues regarding durability.

Fierce Biotech specifically notes that durability concerns contributed to the failure of the autoimmune cell therapy. The consistency across Reuters, STAT, and other sources underscores the severity of the situation, linking the high percentage of staff cuts directly to the trial outcomes and the cessation of the AlloNK® development. This development is significant because it represents a total strategic pivot or shutdown for Artiva Biotherapeutics. The context provided by the coverage suggests that the company had staked its current trajectory on the success of its autoimmune cell therapy trials. The loss of two patients in a clinical setting typically triggers intense regulatory scrutiny and internal review, which in this instance has led to the decision to quit the work entirely. By cutting nearly all of its staff, Artiva is signaling that it no longer has the resources or the viable product pipeline to maintain its previous organizational structure.

Moving forward, observers will be monitoring the final stages of Artiva's wind-down or any potential remaining operations not covered by the 94% layoff. Based on the reports from Yahoo Finance and other news agencies, the primary focus remains on the discontinuation of the AlloNK® program. There is no information in the current coverage regarding whether any other programs survive or if the company will seek a complete liquidation. The immediate priority remains the management of the fallout from the patient deaths and the execution of the announced workforce reductions.